SEARCH

SEARCH BY CITATION

References

  • Aiba, A., Kano, M., Chen, C., Stanton, M.E., Fox, G.D., Herrup, K., Zwingman, T.A., and Tonegawa, S. (1994). Deficient cerebellar long-term depression and impaired motor learning in mGluR1 mutant mice. Cell 79, 377388.
  • Alagarsamy, S., Rouse, S.T., Junge, C., Hubert, G.W., Gutman, D., Smith, Y., and Conn, P.J. (2002). NMDA-induced phosphorylation and regulation of mGluR5. Pharmacol. Biochem. Behav. 73, 299306.
  • Arcella, A., Carpinelli, G., Battaglia, G., D’onofrio, M., Santoro, F., Ngomba, R.T., Bruno, V., Casolini, P., Giangaspero, F., and Nicoletti, F. (2005). Pharmacological blockade of group II metabotropic glutamate receptors reduces the growth of glioma cells in vivo. Neuro-Oncol. 7, 236245.
  • Bhola, N.E., and Grandis, J.R. (2008). Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer. Front. Biosci. 13, 18571865.
  • Bollag, G., Hirth, P., Tsai, J. et al. (2010). Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596599.
  • Brazel, C.Y., Nunez, J.L., Yang, Z., and Levison, S.W. (2005). Glutamate enhances survival and proliferation of neural progenitors derived from the subventricular zone. Neuroscience 131, 5565.
  • Busciglio, J., and Yankner, B.A. (1995). Apoptosis and increased generation of reactive oxygen species in Down’s syndrome neurons in vitro. Nature 378, 776779.
  • Cappuccio, I., Spinsanti, P., Porcellini, A., Desiderati, F., De Vita, T., Storto, M., Capobianco, L., Battaglia, G., Nicoletti, F., and Melchiorri, D. (2005). Endogenous activation of mGlu5 metabotropic glutamate receptors supports self-renewal of cultured mouse embryonic stem cells. Neuropharmacology 49(Suppl. 1), 196205.
  • Cardenas-Navia, L.I., Cruz, P., Lin, J.C., Rosenberg, S.A., and Samuels, Y. (2010). Novel somatic mutations in heterotrimeric G proteins in melanoma. Cancer Biol. Ther. 10, 3337.
  • Chang, H.J., Yoo, B.C., Lim, S.B., Jeong, S.Y., Kim, W.H., and Park, J.G. (2005). Metabotropic glutamate receptor 4 expression in colorectal carcinoma and its prognostic significance. Clin. Cancer Res. 11, 32883295.
  • Chapman, P.B., Hauschild, A., Robert, C. et al. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 25072516.
  • Chen, S., Teicher, L.C., Kazim, D., Pollack, R.E., and Wise, L.S. (1989). Commitment of mouse fibroblasts to adipocyte differentiation by DNA transfection. Science 244, 582585.
  • Chen, S., Zhu, H., Wetzel, W.J., and Philbert, M.A. (1996). Spontaneous melanocytosis in transgenic mice. J. Invest. Dermatol. 106, 11451151.
  • Chenu, C., Serre, C.M., Raynal, C., Burt-Pichat, B., and Delmas, P.D. (1998). Glutamate receptors are expressed by bone cells and are involved in bone resorption. Bone 22, 295299.
  • Cheung, M., Sharma, A., Madhunapantula, S.V., and Robertson, G.P. (2008). Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res. 68, 34293439.
  • Choi, K.Y., Chang, K., Pickel, J.M., Badger II, J.D., and Roche, K.W. (2011). Expression of the metabotropic glutamate receptor 5 (mGluR5) induces melanoma in transgenic mice. Proc. Natl Acad. Sci. U S A 108, 1521915224.
  • Ciceroni, C., Arcella, A., Mosillo, P. et al. (2008). Type-3 metabotropic glutamate receptors negatively modulate bone morphogenetic protein receptor signaling and support the tumourigenic potential of glioma-initiating cells. Neuropharmacology 55, 568576.
  • Curtis, D.R., Phillis, J.W., and Watkins, J.C. (1959). Chemical excitation of spinal neurones. Nature 183, 611612.
  • Dankort, D., Curley, D.P., Cartlidge, R.A., Nelson, B., Karnezis, A.N., Damsky Jr, W.E., You, M.J., Depinho, R.A., McMahon, M., and Bosenberg, M. (2009). Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 41, 544552.
  • Degenhardt, K., and White, E. (2006). A mouse model system to genetically dissect the molecular mechanisms regulating tumorigenesis. Clin Cancer Res. 12, 52985304.
  • Denda, M., Fuziwara, S., and Inoue, K. (2003). Influx of calcium and chloride ions into epidermal keratinocytes regulates exocytosis of epidermal lamellar bodies and skin permeability barrier homeostasis. J. Invest. Dermatol. 121, 362367.
  • Doble, A. (1996). The pharmacology and mechanism of action of riluzole. Neurology 47, S233S241.
  • D’Onofrio, M., Arcella, A., Bruno, V., Ngomba, R.T., Battaglia, G., Lombari, V., Ragona, G., Calogero, A., and Nicoletti, F. (2003). Pharmacological blockade of mGlu2/3 metabotropic glutamate receptors reduces cell proliferation in cultured human glioma cells. J. Neurochem. 84, 12881295.
  • Fischer, M., Glanz, D., William, T., Klapperstuck, T., Wohlrab, J., and Marsch, W. (2004). N-methyl-D-aspartate receptors influence the intracellular calcium concentration of keratinocytes. Exp. Dermatol. 13, 512519.
  • Fischer, M., Glanz, D., Urbatzka, M., Brzoska, T., and Abels, C. (2009). Keratinocytes: a source of the transmitter L-glutamate in the epidermis. Exp. Dermatol. 18, 10641066.
  • Flaherty, K.T., Puzanov, I., Kim, K.B. et al. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809819.
  • Frati, C., Marchese, C., Fisichella, G., Copani, A., Nasca, M.R., Storto, M., and Nicoletti, F. (2000). Expression of functional mGlu5 metabotropic glutamate receptors in human melanocytes. J. Cell. Physiol. 183, 364372.
  • Frizzo, M.E., Dall’onder, L.P., Dalcin, K.B., and Souza, D.O. (2004). Riluzole enhances glutamate uptake in rat astrocyte cultures. Cell. Mol. Neurobiol. 24, 123128.
  • Fuziwara, S., Inoue, K., and Denda, M. (2003). NMDA-type glutamate receptor is associated with cutaneous barrier homeostasis. J. Invest. Dermatol. 120, 10231029.
  • Genever, P.G., Maxfield, S.J., Kennovin, G.D., Maltman, J., Bowgen, C.J., Raxworthy, M.J., and Skerry, T.M. (1999). Evidence for a novel glutamate-mediated signaling pathway in keratinocytes. J. Invest. Dermatol. 112, 337342.
  • Gil-Sanz, C., Delgado-Garcia, J.M., Fairen, A., and Gruart, A. (2008). Involvement of the mGluR1 receptor in hippocampal synaptic plasticity and associative learning in behaving mice. Cereb. Cortex 18, 16531663.
  • Graham, T.E., Sgro, V., Friars, D., and Gibala, M.J. (2000). Glutamate ingestion: the plasma and muscle free amino acid pools of resting humans. Am. J. Physiol. Endocrinol. Metab. 278, E83E89.
  • Gu, Y., and Publicover, S.J. (2000). Expression of functional metabotropic glutamate receptors in primary cultured rat osteoblasts. Cross-talk with N-methyl-D-aspartate receptors. J. Biol. Chem. 275, 3425234259.
  • Guo, W., Zhao, Y., Zhang, Z. et al. (2011). Disruption of xCT inhibits cell growth via the ROS/autophagy pathway in hepatocellular carcinoma. Cancer Lett. 312, 5561.
  • Gutkind, J.S., Novotny, E.A., Brann, M.R., and Robbins, K.C. (1991). Muscarinic acetylcholine receptor subtypes as agonist-dependent oncogenes. Proc. Natl Acad. Sci. U S A 88, 47034707.
  • Hayashi, T. (1952). A physiological study of epileptic seizures following cortical stimulation in animals and its application to human clinics. Jpn. J. Physiol. 3, 4664.
  • Hodgkinson, C.A., Moore, K.J., Nakayama, A., Steingrimsson, E., Copeland, N.G., Jenkins, N.A., and Arnheiter, H. (1993). Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein. Cell 74, 395404.
  • Hoogduijn, M.J., Hitchcock, I.S., Smit, N.P., Gillbro, J.M., Schallreuter, K.U., and Genever, P.G. (2006). Glutamate receptors on human melanocytes regulate the expression of MiTF. Pigment Cell Res. 19, 5867.
  • Hornyak, T.J., Hayes, D.J., Chiu, L.Y., and Ziff, E.B. (2001). Transcription factors in melanocyte development: distinct roles for Pax-3 and Mitf. Mech. Dev. 101, 4759.
  • Johannessen, C.M., Boehm, J.S., Kim, S.Y. et al. (2010). COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968972.
  • Julius, D., Livelli, T.J., Jessell, T.M., and Axel, R. (1989). Ectopic expression of the serotonin 1c receptor and the triggering of malignant transformation. Science 244, 10571062.
  • Kaelin Jr, W.G., and Thompson, C.B. (2010). Q&A: cancer: clues from cell metabolism. Nature 465, 562564.
  • Kato, S., Negishi, K., Mawatari, K., and Kuo, C.H. (1992). A mechanism for glutamate toxicity in the C6 glioma cells involving inhibition of cystine uptake leading to glutathione depletion. Neuroscience 48, 903914.
  • Khan, A.J., Wall, B., Ahlawat, S., Green, C., Schiff, D., Mehnert, J.M., Goydos, J.S., Chen, S., and Haffty, B.G. (2011). Riluzole enhances ionizing radiation-induced cytotoxicity in human melanoma cells that ectopically express metabotropic glutamate receptor 1 in vitro and in vivo. Clin. Cancer Res. 17, 18071814.
  • Kusters-Vandevelde, H.V., Klaasen, A., Kusters, B., Groenen, P.J., Van Engen-Van Grunsven, I.A., Van Dijk, M.R., Reifenberger, G., Wesseling, P., and Blokx, W.A. (2010). Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system. Acta Neuropathol. 119, 317323.
  • Lee, H.J., Wall, B.A., Wangari-Talbot, J., Shin, S.S., Rosenberg, S.A., Chan, J.L., Namkoong, J., Goydos, J.S., and Chen, S. (2011). Glutamatergic pathway targeting in melanoma; single agent and combinatorial therapies. Clin. Cancer Res. 17, 70807092.
  • Maehama, T., and Dixon, J.E. (1998). The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 273, 1337513378.
  • Mao, L., and Wang, J.Q. (2002). Interactions between ionotropic and metabotropic glutamate receptors regulate cAMP response element-binding protein phosphorylation in cultured striatal neurons. Neuroscience 115, 395402.
  • Marin, Y.E., Namkoong, J., Shin, S.S., Raines, J., Degenhardt, K., White, E., and Chen, S. (2005). Grm5 expression is not required for the oncogenic role of Grm1 in melanocytes. Neuropharmacology 49(Suppl. 1), 7079.
  • Minoshima, T., and Nakanishi, S. (1999). Structural organization of the mouse metabotropic glutamate receptor subtype 3 gene and its regulation by growth factors in cultured cortical astrocytes. J. Biochem. 126, 889896.
  • Morhenn, V.B., Waleh, N.S., Mansbridge, J.N., Unson, D., Zolotorev, A., Cline, P., and Toll, L. (1994). Evidence for an NMDA receptor subunit in human keratinocytes and rat cardiocytes. Eur. J. Pharmacol. 268, 409414.
  • Namkoong, J., Shin, S.S., Lee, H.J., Marin, Y.E., Wall, B.A., Goydos, J.S., and Chen, S. (2007). Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma. Cancer Res. 67, 22982305.
  • Nazarian, R., Shi, H., Wang, Q. et al. (2010). Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973977.
  • Nogueira, C., Kim, K.H., Sung, H., Paraiso, K.H., Dannenberg, J.H., Bosenberg, M., Chin, L., and Kim, M. (2010). Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis. Oncogene 29, 62226232.
  • Ogunrinu, T.A., and Sontheimer, H. (2010). Hypoxia increases the dependence of glioma cells on glutathione. J. Biol. Chem. 285, 3771637724.
  • Ohtani, Y., Harada, T., Funasaka, Y., Nakao, K., Takahara, C., Abdel-Daim, M., Sakai, N., Saito, N., Nishigori, C., and Aiba, A. (2008). Metabotropic glutamate receptor subtype-1 is essential for in vivo growth of melanoma. Oncogene 27, 71627170.
  • Okayama, H., Kohno, T., Ishii, Y. et al. (2012). Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res. 72, 100111.
  • Patton, A.J., Genever, P.G., Birch, M.A., Suva, L.J., and Skerry, T.M. (1998). Expression of an N-methyl-D-aspartate-type receptor by human and rat osteoblasts and osteoclasts suggests a novel glutamate signaling pathway in bone. Bone 22, 645649.
  • Peavy, R.D., Chang, M.S., Sanders-Bush, E., and Conn, P.J. (2001). Metabotropic glutamate receptor 5-induced phosphorylation of extracellular signal-regulated kinase in astrocytes depends on transactivation of the epidermal growth factor receptor. J. Neurosci. 21, 96199628.
  • Pereira, C.M., and Oliveira, C.R. (1997). Glutamate toxicity on a PC12 cell line involves glutathione (GSH) depletion and oxidative stress. Free Radic. Biol. Med. 23, 637647.
  • Pollock, P.M., Cohen-Solal, K., Sood, R. et al. (2003). Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat. Genet. 34, 108112.
  • Poulikakos, P.I., Persaud, Y., Janakiraman, M. et al. (2011). RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480, 387390.
  • Prickett, T.D., Wei, X., Cardenas-Navia, I. et al. (2011). Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat. Genet. 43, 11191126.
  • Raynal, C., Delmas, P.D., and Chenu, C. (1996). Bone sialoprotein stimulates in vitro bone resorption. Endocrinology 137, 23472354.
  • Seidlitz, E.P., Sharma, M.K., Saikali, Z., Ghert, M., and Singh, G. (2009). Cancer cell lines release glutamate into the extracellular environment. Clin. Exp. Metastasis 26, 781787.
  • Seidlitz, E.P., Sharma, M.K., and Singh, G. (2010). Extracellular glutamate alters mature osteoclast and osteoblast functions. Can. J. Physiol. Pharmacol. 88, 929936.
  • Shin, S.S., Namkoong, J., Wall, B.A., Gleason, R., Lee, H.J., and Chen, S. (2008). Oncogenic activities of metabotropic glutamate receptor 1 (Grm1) in melanocyte transformation. Pigment Cell Melanoma Res. 21, 368378.
  • Shin, S.S., Wall, B.A., Goydos, J.S., and Chen, S. (2010). AKT2 is a downstream target of metabotropic glutamate receptor 1 (Grm1). Pigment Cell Melanoma Res. 23, 103111.
  • Skeberdis, V.A., Lan, J., Opitz, T., Zheng, X., Bennett, M.V., and Zukin, R.S. (2001). mGluR1-mediated potentiation of NMDA receptors involves a rise in intracellular calcium and activation of protein kinase C. Neuropharmacology 40, 856865.
  • Solit, D.B., Garraway, L.A., Pratilas, C.A. et al. (2006). BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358362.
  • Sontheimer, H. (2008). A role for glutamate in growth and invasion of primary brain tumors. J. Neurochem. 105, 287295.
  • Speyer, C.L., Smith, J.S., Banda, M., Devries, J.A., Mekani, T., and Gorski, D.H. (2011). Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer. Breast Cancer Res. Treat. doi: 10.1007/s10549-011-1624-x.
  • Spinsanti, P., De Vita, T., Di Castro, S., Storto, M., Formisano, P., Nicoletti, F., and Melchiorri, D. (2006). Endogenously activated mGlu5 metabotropic glutamate receptors sustain the increase in c-Myc expression induced by leukaemia inhibitory factor in cultured mouse embryonic stem cells. J. Neurochem. 99, 299307.
  • Takarada-Iemata, M., Takarada, T., Nakamura, Y., Nakatani, E., Hori, O., and Yoneda, Y. (2011). Glutamate preferentially suppresses osteoblastogenesis than adipogenesis through the cystine/glutamate antiporter in mesenchymal stem cells. J. Cell. Physiol. 226, 652665.
  • Thandi, S., Blank, J.L., and Challiss, R.A. (2002). Group-I metabotropic glutamate receptors, mGlu1a and mGlu5a, couple to extracellular signal-regulated kinase (ERK) activation via distinct, but overlapping, signalling pathways. J. Neurochem. 83, 11391153.
  • Van Raamsdonk, C.D., Fitch, K.R., Fuchs, H., De Angelis, M.H., and Barsh, G.S. (2004). Effects of G-protein mutations on skin color. Nat. Genet. 36, 961968.
  • Van Raamsdonk, C.D., Bezrookove, V., Green, G., Bauer, J., Gaugler, L., O’brien, J.M., Simpson, E.M., Barsh, G.S., and Bastian, B.C. (2009). Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457, 599602.
  • Van Raamsdonk, C.D., Griewank, K.G., Crosby, M.B. et al. (2010). Mutations in GNA11 in uveal melanoma. N. Engl. J. Med. 363, 21912199.
  • Villanueva, J., Vultur, A., Lee, J.T. et al. (2010). Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18, 683695.
  • Wang, J.B., Erickson, J.W., Fuji, R. et al. (2010). Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 18, 207219.
  • Wei, X., Walia, V., Lin, J.C. et al. (2011). Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat. Genet. 43, 442446.
  • Wise, D.R., and Thompson, C.B. (2010). Glutamine addiction: a new therapeutic target in cancer. Trends Biochem. Sci. 35, 427433.
  • Wong, C.W., Fan, Y.S., Chan, T.L., Chan, A.S., Ho, L.C., Ma, T.K., Yuen, S.T., and Leung, S.Y. (2005). BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs. J. Clin. Pathol. 58, 640644.
  • Yip, D., Le, M.N., Chan, J.L., Lee, J.H., Mehnert, J.A., Yudd, A., Kempf, J., Shih, W.J., Chen, S., and Goydos, J.S. (2009). A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma. Clin. Cancer Res. 15, 38963902.
  • Young, D., Waitches, G., Birchmeier, C., Fasano, O., and Wigler, M. (1986). Isolation and characterization of a new cellular oncogene encoding a protein with multiple potential transmembrane domains. Cell 45, 711719.